Tics come in a variety of types and frequencies; have a waxing and waning course; are exacerbated by stress, anxiety, and fatigue; and often resolve or improve in the teenage or early adult years. Tourette syndrome requires the presence of chronic, fluctuating motor and phonic tics. In addition to tics, individuals with Tourette syndrome often have a variety of comorbid conditions such as attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, depression and anxiety, episodic outbursts, and academic difficulties. These conditions often are a greater source of difficulty than the tics themselves. All patients with tics should be evaluated to assure proper diagnosis and to identify any associated psychopathology or academic difficulty. The treatment of tics begins with education of the patient and family, including discussions about the fundamentals of tics: their characteristics, etiology, outcomes, and available treatments. Therapy should be individualized based on the extent of impairment, available support, ability to cope, and the presence of other problems. Indications for the treatment of tics include psychosocial problems (loss of self-esteem, comments from peers, excessive worries about tics, diminished participation in activities), functional difficulties, classroom disruption, and physical discomfort. A variety of behavioral approaches can be used. Recent studies have emphasized the value of comprehensive behavioral intervention for tics (CBIT). Because habit reversal is the major component of CBIT, a cooperative patient, the presence of a premonitory urge, and a committed family are essential ingredients for success. If tic-suppressing medication is required, a two-tier approach and monotherapy are recommended. First-tier medications, notably the α-adrenergic agonists, are recommended for individuals with milder tics, especially persons with both tics and ADHD. Second-tier medications include various typical and atypical neuroleptics. Their sequence of prescription is often based on physician experience; I favor pimozide and fluphenazine. Atypical antipsychotics, such as risperidone and aripiprazole, have some advantages based on their side-effect profile and are particularly beneficial in individuals with significant co-existing behavioral issues. As will become readily apparent, however, few medications have been adequately assessed. Deep brain stimulation is an emerging therapy, but further data are required to optimize the location of electrode placement and stimulation and to determine precise indications for its implementation. Stimulant medication is effective in treating ADHD in children with tics; studies reducing concerns about its use are discussed.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Singer HS: Tourette’s syndrome: from behaviour to biology. Lancet Neurol 2005, 4:149–159.
Walkup JT, Ferrao Y, Leckman JF, et al.: Tic disorders: some key issues for DSM-V. Depress Anxiety 2010, 27:600–610.
Khalifa N, von Knorring AL: Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background. Acta Paediatr 2005, 94:1608–1614.
Kurlan R, Como PG, Miller B, et al.: The behavioral spectrum of tic disorders: a community-based study. Neurology 2002, 59:414–420.
Cavanna AE, Eddy C, Rickards HE: Cognitive functioning in Tourette syndrome. Discov Med 2009, 8:191–195.
Pringsheim T, Lang A, Kurlan R, et al.: Understanding disability in Tourette syndrome. Dev Med Child Neurol 2009, 51:468–472.
Mejia NI, Jankovic J: Secondary tics and tourettism. Rev Bras Psiquiatr 2005, 27:11–17.
Bergin A, Waranch HR, Brown J, et al.: Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998, 18:136–142.
O’Connor KP, Laverdure A, Taillon A, et al.: Cognitive behavioral management of Tourette’s syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther 2009, 47:1090–1095.
Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008. Woods DW, Piacentini JC, Chang SW, et al.: Managing Tourette Syndrome: A Behavioral Intervention for Children and Adults. New York: Oxford University Press; 2008.
Himle MB, Woods DW, Piacentini JC, Walkup JT: Brief review of habit reversal training for Tourette syndrome. J Child Neurol 2006, 21:719–725.
Deckersbach T, Rauch S, Buhlmann U, Wilhelm S: Habit reversal versus supportive psychotherapy in Tourette’s disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther 2006, 44:1079–1090.
Piacentini J, Woods DW, Scahill L, et al.: Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010, 303:1929–1937.
Garcia-Lopez R, Romero-Gonzalez J, Perea-Milla E, et al.: [An open study evaluating the efficacy and security of magnesium and vitamin B(6) as a treatment of Tourette syndrome in children.]. Med Clin (Barc) 2008, 131:689–692.
Ma S, Liu XY, Yu RL, Chen LJ: [Clinical observation on acupuncture for treatment of Tourette’s syndrome]. Zhongguo Zhen Jiu 2006, 26:392–394.
Mantovani A, Lisanby SH, Pieraccini F, et al.: Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol 2006, 9:95–100.
Mantovani A, Leckman JF, Grantz H, et al.: Repetitive transcranial magnetic stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol 2007, 118:2314–2315.
Scahill L, Erenberg G, Berlin CM Jr, et al.: Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3:192–206.
Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58:527–536.
Hedderick EF, Morris CM, Singer HS: Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009, 40:420–425.
Gaffney GR, Perry PJ, Lund BC, et al.: Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002, 41:330–336.
Du YS, Li HF, Vance A, et al.: Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust NZ J Psychiatry 2008, 42:807–813.
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF: Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009, 48:884–893.
Scahill L, Chappell PB, Kim YS, et al.: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158:1067–1074.
Cummings DD, Singer HS, Krieger M, et al.: Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002, 25:325–332.
Abuzzahab FS, Brown VL: Control of Tourette’s syndrome with topiramate. Am J Psychiatry 2001, 158:968.
Kuo SH, Jimenez-Shahed J: Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010, 33:32–34.
Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2009, 81:70–73.
Awaad Y, Michon AM, Minarik S: Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005, 20:714–718.
Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B: An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 2009, 13:541–545.
Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS: A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764–1770.
Shapiro AK: Gilles de la Tourette Syndrome. New York: Raven; 1988.
Awaad Y: Tics in Tourette syndrome: new treatment options. J Child Neurol 1999, 14:316–319.
Singer HS, Wendlandt J, Krieger M, Giuliano J: Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599–604.
Drtilkova I, Balaotkova B, Lemanova H, Zak J: Therapeutical effects of clonidine and clonazepam in children with tic syndrome. Homeost Health Dis 1994, 35:296.
Ray WA, Chung CP, Murray KT, et al.: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225–235.
Schneeweiss S, Avorn J: Antipsychotic agents and sudden cardiac death—How should we manage the risk? N Engl J Med 2009, 360:294–296.
Pringsheim T, Marras C: Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2009, CD006996. This comprehensive review of prior studies assessed the benefits and risks of pimozide in comparison to placebo or other medications in treating tics in Tourette syndrome.
Singer HS, Gammon K, Quaskey S: Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985, 12:71–74.
Goetz CG, Tanner CM, Klawans HL: Fluphenazine and multifocal tic disorders. Arch Neurol 1984, 41:271–272.
Jankovic J: Treatment of hyperkinetic movement disorders. Lancet Neurol 2009, 8:844–856.
Shapiro E, Shapiro AK, Fulop G, et al.: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989, 46:722–730.
Scahill L, Leckman JF, Schultz RT, et al.: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130–1135.
Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22:31–39.
Bruggeman R, van der Linden C, Buitelaar JK, et al.: Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001, 62:50–56.
Gilbert DL, Batterson JR, Sethuraman G, Sallee FR: Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004, 43:206–214.
Budman C, Coffey BJ, Shechter R, et al.: Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008, 18:509–515.
Kawohl W, Schneider F, Vernaleken I, Neuner I: Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci 2009, 21:224.
Murphy TK, Mutch PJ, Reid JM, et al.: Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009, 19:441–447.
Davies L, Stern JS, Agrawal N, Robertson MM: A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006, 21:447–453.
Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008, 18:197–205.
Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292–299.
Willmund G, Lee AH, Wertenauer F, et al.: Vocal tics associated with ziprasidone. J Clin Psychopharmacol 2009, 29:611–612.
Budman CL, Gayer A, Lesser M, et al.: An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry 2001, 62:290–294.
McCracken JT, Suddath R, Chang S, et al.: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008, 18:501–508.
Onofrj M, Paci C, D’Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000, 247:443–446.
Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003, 13:295–299.
Copur M, Arpaci B, Demir T, Narin H: Clinical effectiveness of quetiapine in children and adolescents with Tourette’s syndrome: a retrospective case-note survey. Clin Drug Investig 2007, 27:123–130.
Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193–197.
Kenney C, Hunter C, Davidson A, Jankovic J: Short-term effects of tetrabenazine on chorea associated with Huntington’s disease. Mov Disord 2007, 22:10–13.
Porta M, Sassi M, Cavallazzi M, et al.: Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008, 28:443–459.
Simpson DM, Blitzer A, Brashear A, et al.: Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699–1706.
Marras C, Andrews D, Sime E, Lang AE: Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605–610.
Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190–1193.
Rath JJ, Tavy DL, Wertenbroek AA, et al.: Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord 2010, 16:478–481.
Porta M, Maggioni G, Ottaviani F, Schindler A: Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 2004, 24:420–423.
Robertson MM, Schnieden V, Lees AJ: Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990, 13:229–235.
Ho CS, Chen HJ, Chiu NC, et al.: Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009, 108:788–793.
Eggers C, Rothenberger A, Berghaus U: Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988, 237:223–229.
Muller-Vahl KR, Schneider U, Prevedel H, et al.: Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003, 64:459–465.
Singer HS, Morris C, Grados M: Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 2010, 74:862–867.
Cubo E, Fernandez Jaen A, Moreno C, et al.: Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther 2008, 30:182–189.
Bortolato M, Muroni A, Marrosu F: Treatment of Tourette’s syndrome with finasteride. Am J Psychiatry 2007, 164:1914–1915.
Peterson BS, Zhang H, Anderson GM, Leckman JF: A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998, 18:324–331.
Toren P, Weizman A, Ratner S, et al.: Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005, 66:499–503.
Bonnier C, Nassogne MC, Evrard P: Ketanserin treatment of Tourette’s syndrome in children. Am J Psychiatry 1999, 156:1122–1123.
Perlmutter SJ, Leitman SF, Garvey MA, et al.: Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153–1158.
Hoekstra PJ, Minderaa RB, Kallenberg CG: Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. J Clin Psychiatry 2004, 65:537–542.
Neimat JS, Patil PG, Lozano AM: Novel surgical therapies for Tourette syndrome. J Child Neurol 2006, 21:715–718.
Porta M, Sassi M, Ali F, et al.: Neurosurgical treatment for Gilles de la Tourette syndrome: the Italian perspective. J Psychosom Res 2009, 67:585–590.
Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72–76.
Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72–76.
Shields DC, Cheng ML, Flaherty AW, et al.: Microelectrode-guided deep brain stimulation for Tourette syndrome: within-subject comparison of different stimulation sites. Stereotact Funct Neurosurg 2008, 86:87–91.
Temel Y, Visser-Vandewalle V: Surgery in Tourette syndrome. Mov Disord 2004, 19:3–14.
Roessner V, Robatzek M, Knapp G, et al.: First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 2006, 48:616–621.
Erenberg G: The relationship between Tourette syndrome, attention deficit hyperactivity disorder, and stimulant medication: a critical review. Semin Pediatr Neurol 2005, 12:217–221.
Allen AJ, Kurlan RM, Gilbert DL, et al.: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005, 65:1941–1949.
Singer HS, Brown J, Quaskey S, et al.: The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95:74–81.
Spencer T, Biederman J, Coffey B, et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002, 59:649–656.
Storch EA, Bjorgvinsson T, Riemann B, et al.: Factors associated with poor response in cognitive-behavioral therapy for pediatric obsessive-compulsive disorder. Bull Menninger Clin 2010, 74:167–185.
Decloedt EH, Stein DJ: Current trends in drug treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat 2010, 6:233–242.
No potential conflicts of interest relevant to this article were reported.
About this article
Cite this article
Singer, H.S. Treatment of Tics and Tourette Syndrome. Curr Treat Options Neurol 12, 539–561 (2010). https://doi.org/10.1007/s11940-010-0095-4